title: Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels.
abstract: We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58-1.47, P < 0.001). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00-1.69, P < 0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51-1.71, P < 0.001), but not among Turkish population and using INA method (all P > 0.05). Egger's test showed no publication bias (P = 0.450). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.
authors.affiliation: Department of Emergency, Weifang People's Hospital, Weifang 261041, China.
authors.forename: Fang-Cheng
authors.initials: FC
authors.lastname: Su
authors.affiliation: Department of Cardiology, Linyi People's Hospital, Linyi 276003, China.
authors.forename: Xi-Dong
authors.initials: XD
authors.lastname: Li
authors.affiliation: Department of Cardiology, Linyi People's Hospital, Linyi 276003, China.
authors.forename: Shao-Xia
authors.initials: SX
authors.lastname: Sun
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Ming-Yu
authors.initials: MY
authors.lastname: Shi
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Feng-Hua
authors.initials: FH
authors.lastname: Xue
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Shi-Chao
authors.initials: SC
authors.lastname: Teng
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhu
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Yin
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors.forename: Hong-Yue
authors.initials: HY
authors.lastname: Gu
mesh_terms: D000328:Adult; D000069059:Atorvastatin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood* / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017594:Publication Bias
chemical_list: D002097:C-Reactive Protein; D000069059:Atorvastatin